Vita 34 plans a capital increase in the amount of about 10 % close to the current market price with a strategic investor to finance the takeover of Seracell Pharma AG. The supervisory board dismisses the chairman of the Management Board, Dr. André Gerth, with immediate effect and appoints the member of the Supervisory Board and lawyer, Alexander Starke, as a interim member of the Management Board - The Supervisory Board appoints the member of the Management Board, Dr. Wolfgang Knirsch, as the new chairman of the Management Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.5 EUR | +0.45% |
|
-0.44% | -14.12% |
06-01 | VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-30 | VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.12% | 83.85M | |
+20.64% | 83.73B | |
-28.19% | 72.21B | |
-0.35% | 26.2B | |
+1.39% | 17.18B | |
-10.31% | 17.09B | |
+2.19% | 15.18B | |
+78.22% | 13.59B | |
+79.75% | 13.11B | |
-22.98% | 12.92B |
- Stock Market
- Equities
- V3V Stock
- News VITA 34 AG
- VITA 34 AG Announces Management Changes